Medication

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

Monday, October 25, 2021 - 12:50pm

This press release contains statements that constitute forward-looking information (forward-looking information) within the meaning of the applicable Canadian securities legislation.

Key Points: 
  • This press release contains statements that constitute forward-looking information (forward-looking information) within the meaning of the applicable Canadian securities legislation.
  • In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions.
  • Small Pharma makes no medical, treatment or health benefit claims about its proposed products.
  • If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharmas performance and operations.

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

Monday, October 25, 2021 - 1:00pm

The company will host a conference call and webcast on the same day at 9:05 a.m.

Key Points: 
  • The company will host a conference call and webcast on the same day at 9:05 a.m.
  • The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 7582968.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals website at www.x4pharma.com .
  • Following the completion of the call, a webcast replay of the conference call will be available on the website.

Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder

Monday, October 25, 2021 - 1:01pm

The Loulou Foundation will serve as the study coordinator, and the study will involve CDD clinical centers worldwide.

Key Points: 
  • The Loulou Foundation will serve as the study coordinator, and the study will involve CDD clinical centers worldwide.
  • At Marinus, we are developing ganaxolone, an investigational drug for the treatment of rare epilepsies, including CDD, said Alex Aimetti, Ph.D., Vice President, Scientific Affairs at Marinus Pharmaceuticals.
  • We are privileged to be adding to the scientific knowledge about this serious disorder and to be able to support the CDD community by partnering with the Loulou Foundation on this study.
  • The CANDID study aims to provide researchers with information on the suitability of clinical assessments across multiple domains.

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

Monday, October 25, 2021 - 12:15pm

"Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries," said Marc Rubin, M.D., Executive Chairman of Titan.

Key Points: 
  • "Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries," said Marc Rubin, M.D., Executive Chairman of Titan.
  • The continuous long-term delivery of a contraceptive/antiviral combination has the potential to have a greater public health impact in developing nations, compared with daily dosing of multiple compounds."
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeuralong-term, continuous drug delivery technology.
  • Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease

Monday, October 25, 2021 - 12:00pm

DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLEX as the first and only nonsurgical FDA-approved treatment for Peyronie's disease (PD) and encourages them to seek treatment if they believe they may have the condition, in which a buildup of fibrous scar tissue (plaque) causes a curvature of the penis.

Key Points: 
  • Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection.
  • Before receiving XIAFLEX, tell your healthcare provider if youhave had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease

Monday, October 25, 2021 - 12:00pm

DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLEX as the first and only nonsurgical FDA-approved treatment for Peyronie's disease (PD) and encourages them to seek treatment if they believe they may have the condition, in which a buildup of fibrous scar tissue (plaque) causes a curvature of the penis.

Key Points: 
  • Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection.
  • Before receiving XIAFLEX, tell your healthcare provider if youhave had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Worldwide Pharmaceutical Analytical Testing Industry to 2026 - Increasing Number of Clinical Trials is Driving Growth - ResearchAndMarkets.com

Monday, October 25, 2021 - 11:45am

The stability testing is done on the basis of five parameters : Chemical, physical, microbiological, therapeutic and toxicity.

Key Points: 
  • The stability testing is done on the basis of five parameters : Chemical, physical, microbiological, therapeutic and toxicity.
  • According to the study published by Journal of Industrial Microbiology & Biotechnology, almost 300 biopharmaceuticals have been patented in the last three decaded.
  • North America is expected to be a dominant region in the Pharmaceutical Analytical Testing market owing to increasing number of R&D activities and investments on it.
  • Thus, the increasing number of clinical trials and number of approved drugs is expected to boost up the demand of pharmaceutical analytical testing market growth in the North America Region.

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Monday, October 25, 2021 - 12:00pm

We are very pleased to have completed enrollment in the first of our two planned pivotal registration trials.

Key Points: 
  • We are very pleased to have completed enrollment in the first of our two planned pivotal registration trials.
  • The THRIVE-AA clinical program includes two Phase 3 studies, THRIVE-AA1 and THRIVE-AA2.
  • THRIVE-AA1 (NCT04518995) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT).
  • Concerts lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition.

Global Antibody Drug Conjugates Market Research Report 2021: COVID-19 Growth and Change to 2025 & 2030 - ResearchAndMarkets.com

Friday, October 22, 2021 - 12:13pm

The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The challenges involved in the manufacturing of ADC's is acting as a restraint on the antibody drug conjugates market.
  • Global Antibody Drug Conjugates Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
    6.2.
  • Global Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21

Friday, October 22, 2021 - 12:00pm

EANM is the largest organization dedicated to nuclear medicine in Europe and represents more than 9,000 specialists from 41 different countries.

Key Points: 
  • EANM is the largest organization dedicated to nuclear medicine in Europe and represents more than 9,000 specialists from 41 different countries.
  • Our preclinical studies with antibody-drug conjugate forms of ifabotuzumab have shown promising results.
  • The Olivia Newton-John Cancer Research Institute plans to conduct a Phase 1b dose-escalation and imaging study in non-CNS solid tumors that is scheduled to begin in early 2022.
  • We look forward to supporting our valued partners in Australia as they advance research of ifabotuzumab into solid tumors.